419 related articles for article (PubMed ID: 16291771)
41. Exogenous progestagens and the human breast.
Sitruk-Ware R; Plu-Bureau G
Maturitas; 2004 Sep; 49(1):58-66. PubMed ID: 15351097
[TBL] [Abstract][Full Text] [Related]
42. Evolution of progestins. Focus on the novel progestin drospirenone.
Thorneycroft IH
J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671
[TBL] [Abstract][Full Text] [Related]
43. Contraceptive progestins. Various 11-substituents combined with four 17-substituents: 17alpha-ethynyl, five- and six-membered spiromethylene ethers or six-membered spiromethylene lactones.
Schoonen WG; Deckers G; de Gooijer ME; de Ries R; Mathijssen-Mommers G; Hamersma H; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2000 Oct; 74(3):109-23. PubMed ID: 11086230
[TBL] [Abstract][Full Text] [Related]
44. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome.
Morgante G; Cappelli V; Troìa L; De Leo V
Eur J Contracept Reprod Health Care; 2020 Jun; 25(3):176-181. PubMed ID: 32191532
[No Abstract] [Full Text] [Related]
46. Effects of progestins of human proliferative endometrium: an in vitro model of potential clinical relevance.
Illouz S; Dales JP; Sferlazzo K; Garcia S; Carpentier-Meunier S; Boubli L; Lavaut MN; Charpin C
Int J Mol Med; 2003 Oct; 12(4):517-23. PubMed ID: 12964029
[TBL] [Abstract][Full Text] [Related]
47. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells.
Schneck H; Ruan X; Seeger H; Cahill MA; Fehm T; Mueck AO; Neubauer H
Gynecol Endocrinol; 2013 Feb; 29(2):160-3. PubMed ID: 23116217
[TBL] [Abstract][Full Text] [Related]
48. [Actions of a 19-norprogesterone derivative on mammary gland: nomegestrol acetate].
André G
J Gynecol Obstet Biol Reprod (Paris); 2005 Feb; 34(1 Pt 1):69-84. PubMed ID: 15767920
[TBL] [Abstract][Full Text] [Related]
49. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception.
Africander D; Verhoog N; Hapgood JP
Steroids; 2011 Jun; 76(7):636-52. PubMed ID: 21414337
[TBL] [Abstract][Full Text] [Related]
50. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.
Bray JD; Jelinsky S; Ghatge R; Bray JA; Tunkey C; Saraf K; Jacobsen BM; Richer JK; Brown EL; Winneker RC; Horwitz KB; Lyttle CR
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):328-41. PubMed ID: 16157482
[TBL] [Abstract][Full Text] [Related]
51. Contraceptives with novel benefits.
Su Y; Lian QQ; Ge RS
Expert Opin Investig Drugs; 2012 Jan; 21(1):83-90. PubMed ID: 22149760
[TBL] [Abstract][Full Text] [Related]
52. Hormone therapy and the cardiovascular system: the critical role of progestins.
Sitruk-Ware RL
Climacteric; 2003 Oct; 6 Suppl 3():21-8. PubMed ID: 15018245
[TBL] [Abstract][Full Text] [Related]
53. Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate.
Simoncini T; Caruso A; Garibaldi S; Fu XD; Giretti MS; Baldacci C; Scorticati C; Fornari L; Mannella P; Genazzani AR
Obstet Gynecol; 2006 Oct; 108(4):969-78. PubMed ID: 17012461
[TBL] [Abstract][Full Text] [Related]
54. In vitro characterization of trimegestone: a new potent and selective progestin.
Zhang Z; Lundeen SG; Zhu Y; Carver JM; Winneker RC
Steroids; 2000; 65(10-11):637-43. PubMed ID: 11108870
[TBL] [Abstract][Full Text] [Related]
55. Parenteral administration of progestins for hormonal replacement therapy.
Nath A; Sitruk-Ware R
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):88-96. PubMed ID: 19340703
[TBL] [Abstract][Full Text] [Related]
56. Psychosexual well-being in women using oral contraceptives containing drospirenone.
Nappi RE; Albani F; Tonani S; Santamaria V; Pisani C; Terreno E; Martini E; Polatti F
Funct Neurol; 2009; 24(2):71-5. PubMed ID: 19775533
[TBL] [Abstract][Full Text] [Related]
57. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.
Sasagawa S; Shimizu Y; Kami H; Takeuchi T; Mita S; Imada K; Kato S; Mizuguchi K
Steroids; 2008 Feb; 73(2):222-31. PubMed ID: 18061638
[TBL] [Abstract][Full Text] [Related]
58. Metabolic and clinical effects of progestogens.
Wiegratz I; Kuhl H
Eur J Contracept Reprod Health Care; 2006 Sep; 11(3):153-61. PubMed ID: 17056444
[TBL] [Abstract][Full Text] [Related]
59. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
60. Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat.
Attardi BJ; Koduri S; Hild SA
Mol Cell Endocrinol; 2010 Oct; 328(1-2):16-21. PubMed ID: 20599585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
